What the FDA labels say about taking them together
Crovalimab and eculizumab
Crovalimab's FDA label of November 11, 2025 names eculizumab in its drug interactions section; the eculizumab labels PlainMeds reads (3) do not name crovalimab. The crovalimab label: “Related to Drug-Target-Drug Complexes Patients who are switching from another C5 inhibitor to PIASKY or from PIASKY to another C5 inhibitor are at risk of serious Type III hypersensitivity reactions related to the …”
Check it at the source: the crovalimab FDA label on DailyMed (effective November 11, 2025); the eculizumab FDA label on DailyMed (effective July 8, 2026, Alexion Pharmaceuticals Inc.).
What does the crovalimab label say about eculizumab?
Crovalimab label, drug interactionsDRUG INTERACTIONS PIASKY binds different epitopes on C5 compared to eculizumab and ravulizumab, which can lead to the formation of DTDCs when patients switch between PIASKY and either eculizumab or ravulizumab.
Crovalimab label, warnings and precautionsRelated to Drug-Target-Drug Complexes Patients who are switching from another C5 inhibitor (e.g., eculizumab or ravulizumab) to PIASKY or from PIASKY to another C5 inhibitor are at risk of serious Type III hypersensitivity reactions related to the formation of drug-target-drug-complexes (DTDCs), because PIASKY and these other C5 inhibitors bind different epitopes of C5 [see Drug Interactions (7) ].
Source: FDA drug label (Piasky), Genentech, Inc., effective November 11, 2025 (SPL set 2597efc2-a97b-487c-b500-a67fd282a73b), via openFDA; the full label on DailyMed
What does the eculizumab label say about crovalimab?
Eculizumab's label (effective July 8, 2026) and its 2 other brand-application labels do not name crovalimab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SOLIRIS), Alexion Pharmaceuticals Inc., effective July 8, 2026 (SPL set ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Crovalimab | Eculizumab | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once